For extremely high-risk patients who had an IS (stroke plus another major atherosclerotic cardiovascular disease (ASCVD) event or stroke plus multiple high-risk factors), if LDL-C levels remain above 1.8 mmol/L despite receiving maximum tolerated statin and ezetimibe combination therapy, the use of PCSK9 inhibitors is recommended to prevent ASCVD events. Here, PCSK9 is linked to stroke disorder.